Indications -- Sepsis/Acute Inflammation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Sepsis/Acute Inflammation

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: A.J. Mullen who wrote (45)	12/9/2005 11:39:22 AM
From: tuck	Read Replies (1) of 89

OT Ashley, The Hart-Scott-Rodino act specifies a certain length of time during which the federal government may examine a proposed merger (or a buy of someone's business, if not the whole company) for anti-trust impact. If the period expires, that means the Feds have given their blessing to the transaction. If the impact is deemed to be large, i.e. they are worried the transaction may create a monopoly, they may nix the transaction or require certain parts of the acquired entity to be divested, so long as they inform the companies involved before the waiting period expires. Can't remember which agency does the oversight; it's either the Dept. of Justice, Commerce, or the FCC. Not likely to be a problem for Protherics. In some cases, when big pharmas have merged, certain drugs had to be sold to satisfy the feds. This has occasionally created opportunities for other healthcare companies to buy a good drug at a reasonable price. Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next